Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 12,313 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 12,313 shares of the stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $28.82, for a total transaction of $354,860.66. Following the sale, the chief financial officer directly owned 251,804 shares in the company, valued at $7,256,991.28. This trade represents a 4.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Wednesday, August 19th, Oluyemi Okupe sold 4,938 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.99, for a total transaction of $148,090.62.
• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.89, for a total transaction of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total transaction of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The stock was sold at an average price of $34.03, for a total transaction of $619,243.91.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $28.00 on Friday. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $65.30. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The stock has a market capitalization of $6.53 billion, a PE ratio of -44.45 and a beta of 2.42. The stock’s 50-day moving average price is $30.06 and its 200-day moving average price is $27.60.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The business had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. Hims & Hers Health’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.17 EPS. As a group, equities analysts expect that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

Several large investors have recently made changes to their positions in the company. Cunning Capital Partners LP purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth $1,110,000. Norges Bank purchased a new position in shares of Hims & Hers Health in the fourth quarter worth about $62,153,000. Virtu Financial LLC acquired a new position in Hims & Hers Health during the fourth quarter worth about $1,937,000. Louisiana State Employees Retirement System acquired a new position in Hims & Hers Health during the first quarter worth about $1,254,000. Finally, X Square Capital LLC grew its stake in Hims & Hers Health by 9.7% during the 4th quarter. X Square Capital LLC now owns 468,999 shares of the company’s stock valued at $15,228,000 after acquiring an additional 41,408 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HIMS. Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Wall Street Zen upgraded shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Needham & Company LLC boosted their target price on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, UBS Group set a $23.00 price target on shares of Hims & Hers Health in a research report on Friday, May 22nd. Three analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $32.43.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Neutral Sentiment: CFO Oluyemi Okupe sold 12,313 shares worth approximately $355,000, reducing his position by 4.66%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, making it a weaker standalone bearish signal. CFO SEC filing
• Neutral Sentiment: COO Michael Chi sold 14,027 shares for about $398,000, while insider Soleil Boughton sold 6,236 shares for approximately $174,000. Both sales were made through pre-arranged Rule 10b5-1 plans; however, the cluster of insider sales may still reinforce investor caution. Insider SEC filing
• Negative Sentiment: Multiple law firms announced or promoted a securities class action against HIMS involving investors who purchased shares between August 4, 2025, and July 29, 2026. The deadline to seek lead-plaintiff status is November 2, 2026, increasing headline and litigation risk. Securities class action report
• Negative Sentiment: The lawsuits stem from allegations related to the FTC’s complaint, including potential misstatements or omissions concerning Hims & Hers’ privacy, data-sharing, billing and business practices. The allegations remain unproven, but could lead to legal costs, regulatory consequences and reputational damage. HIMS lawsuit allegations

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.